• Jyoti Upadhyay KUMAUN UNIVERSITY
  • Gaurav Upadhyay
  • Amita Joshi Rana


Objective: Epilepsy is the second most common neurologic disorder after stroke. The study was undertaken to determine the prevalence of epilepsy
disorders and drug utilization pattern in a patient population of Dehradun. This study was conducted in a private health clinic.
Methods: A questionnaire was prepared that includes many practical questions regarding epilepsy seizure type, medication prescribed, their health
status, and compliance. A total of 200 cases of epilepsy were reported.
Results: The study showed the prevalence of epilepsy disorders which was most common among males (65%) as compared to females (35%). 44%
of epilepsy disorders were found prevalent among the age group between 30 and 40 years. The most common type of epilepsy disorder is primary
generalized seizure (62%) followed by partial seizures (23%), focal disorder (6%), grand mal cortical focal epilepsy (5%), typical seizures (3.5%),
refractory seizures (3%), and others (2.5%).
Conclusion: Epilepsy is one of the most serious neurological disorders in terms of both prevalence and cumulative incidence. Good education and
counseling is required for coping up the challenges of this condition as well for improving patient compliance. For decreasing the chances of adverse
effects and avoiding drug interactions monotherapy is important. Health-care providers and patients can together formulate a better therapeutic plan
for achieving a seizure-free status without adverse effects.
Keywords: Seizures, Antiepileptic drugs, Compliance.

Author Biography


Research Scholar

Department of Pharmaceutical Sciences


1. Epilepsy Foundation. Epilepsy and Seizure Statistics. Available from: http://www.epilepsyfoundation.org/about/statistics.cfm. [Last accessed on 2010 Dec 31].
2. Hesdorffer DC, Logroscino G, Benn EK, Katri N, Cascino G, Hauser WA. Estimating risk for developing epilepsy: A population-based study in Rochester, Minnesota. Neurology 2011;76(1):23-7.
3. Kale R. Bringing epilepsy out of the shadows. BMJ 1997;315(7099):2-3.
4. Tripathi KD. Essentials of Medical Pharmacology. 6th ed. New Delhi: Jaypee Publication; 2008. p. 401.
5. Walker R, Edwards C. Clinical Pharmacy and Therapeutics. Philadelphia, PA: Lippincott Williams and Wilkins; 2003. p. 127-39, 447.
6. Howland RD, Mycek MJ. Lippincott’s Illustrated Reviews: Pharmacology. 3rd ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2006. p. 169.
7. Perucca E, Tomson T. The pharmacological treatment of epilepsy in adults. Lancet Neurol 2011;10(5):446-56.
8. International League against Epilepsy/International Bureau for Epilepsy/World Health Organization Global Campaign against Epilepsy. Epilepsy in the WHO European Region. 2010. Available from: http://www.ibe-epilepsy.org/downloads/EURO%20Report%20160510.pdf. [Last accessed on 2010 Dec 31].
9. Tomson T, Beghi E, Sundqvist A, Johannessen SI. Medical risks in epilepsy: A review with focus on physical injuries, mortality, traffic accidents and their prevention. Epilepsy Res 2004;60(1):1-16.
10. The Lancet Neurology. Epilepsy must become a higher priority in Europe. Lancet Neurol 2010;9(10):941.
492 Views | 325 Downloads
How to Cite
Upadhyay, J., G. Upadhyay, and A. J. Rana. “A PROSPECTIVE STUDY ON PREVALENCE OF EPILEPSY DISORDERS AND DRUG UTILIZATION PATTERN”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 10, no. 3, Mar. 2017, pp. 136-9, doi:10.22159/ajpcr.2017.v10i3.15605.
Original Article(s)